Patients dropping MS drug Tysabri face relapse risk

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis

Patients dropping MS drug Tysabri face relapse risk

Postby MSUK » Thu Apr 26, 2012 2:55 am


Multiple sclerosis patients treated with natalizumab were more likely to discontinue therapy after learning of a positive JCV antibody result, only to see a higher risk for relapse, according to a small, single-center study reported here.

Of nine patients who discontinued natalizumab (Tysabri) after learning their antibody result, which indicated a heightened risk for progressive multifocal leukoencephalopathy (PML) -- a rare but life-threatening event -- five relapsed within 6 months, said Denise Cheng, RN, of Winthrop Comprehensive MS Care Center in Mineola, N.Y.

These patients may have assumed their MS was no longer active, as opposed to a continuing disease process that was suppressed by the natalizumab treatment, Cheng said at the American Academy of Neurology's annual meeting....Read More - ... ageid/1768
User avatar
Family Elder
Posts: 2461
Joined: Wed Oct 14, 2009 3:00 pm


Return to Tysabri (Antegren or Natalizumab)


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service